孙晓革,宝莹娜,邱惠,石静,张薇,郁志龙,谢丛华.PBK和基质金属蛋白酶9在宫颈癌中的表达及对同步放化疗疗效的影响[J].中华放射医学与防护杂志,2018,38(7):529-534
PBK和基质金属蛋白酶9在宫颈癌中的表达及对同步放化疗疗效的影响
Expressions of PBK and MMP-9 and their effect on concurrent chemoradiotherapy in cervical cancer
投稿时间:2018-04-09  
DOI:10.3760/cma.j.issn.0254-5098.2018.07.009
中文关键词:  PBK(PDZ连接激酶)  基质金属蛋白酶9  同步放化疗  宫颈癌
英文关键词:PBK(PDZ binding kinase)  Matrix metalloproteinase 9(MMP-9)  Concurrent chemoradiotherapy  Cervical cancer
基金项目:内蒙古自治区自然科学基金项目(2016MS0856)
作者单位E-mail
孙晓革 430071 武汉大学中南医院放疗科  
宝莹娜 010050 呼和浩特, 内蒙古医科大学附属医院放疗科  
邱惠 430071 武汉大学中南医院放疗科  
石静 010050 呼和浩特, 内蒙古医科大学附属医院放疗科  
张薇 010050 呼和浩特, 内蒙古医科大学附属医院放疗科  
郁志龙 010050 呼和浩特, 内蒙古医科大学附属医院放疗科  
谢丛华 430071 武汉大学中南医院放疗科 chxie_65@whu.edu.cn 
摘要点击次数: 2683
全文下载次数: 1496
中文摘要:
      目的 探讨DNA损伤修复因子PBK(PDZ连接激酶)和基质金属蛋白酶9(MMP-9)在宫颈癌中的表达及对同步放化疗疗效的影响。方法 收集2014年1月至2016年7月共65例宫颈鳞癌根治性同步放化疗患者的病理标本,通过免疫组织化学法检测PBK和MMP-9的表达情况。体外照射采用调强放射治疗,剂量为50 Gy/25次;外照射18次后予以高剂量率后装治疗,30~36 Gy/5~6次,3~4周。外照射开始后给予每周化疗,采用单药顺铂方案,顺铂(DDP)40 mg/m2静脉滴注,连续2~6周。定期随访所有患者,分析患者临床特征、预后与PBK和MMP-9之间的关系。结果 PBK在宫颈癌标本中的阳性表达率为92.3%,MMP-9为69.2%。PBK高表达组的宫颈癌患者总生存率(OS)和疾病无进展生存率(PFS)均明显低于PBK表达低的患者(χ2=4.324、8.068,P<0.05),MMP-9高表达组患者的PFS明显低于低表达组(χ2=5.134,P<0.05),PBK和MMP-9联合高表达组的OS和PFS比联合低表达组低(χ2=5.382、9.364,P<0.05)。结论 PBK和MMP-9在宫颈癌组织中的表达存在差异与宫颈癌的预后相关,联合检测PBK和MMP-9的表达水平可能有助于预测宫颈癌同步放化疗后的疗效。
英文摘要:
      Objective To investigate the expression of DNA damage repair factor PDZ binding kinase (PBK) and matrix metalloproteinase 9 (MMP-9) in cervical cancer and the effect on clinical outcomes of concurrent chemoradiotherapy. Methods A total of 65 cervical cancer pathological specimens were collected from January 2014 to July 2016. Immunohistochemistry was used to detect PBK and MMP-9 expression in the specimens.External irrsdeation was treated with intensity-modulated radiation therapy at a dose of 50 Gy/25 F. After 18 times of external irradiation, high-dose rate postoperative treatment was giver at a dose of 30-36 Gy/5-6 F which lasts 3-4 weeks. Weekly chemotherapy with Cisplatin(DDP) begins simultaneously at the beginning of external irradiation. DDP was administered intravenously at a dosage of 40 mg/m2 for 2 to 6 week. All patients were followed-up as routine. The relationship between clinical characteristics and prognosis of patients and the expression of PBK and MMP-9 were analyzed. Results PBK was expressed in 92.3% of tissues and MMP-9 was expressed in 69.2% of tissues. The expression of PBK was positively associated with overall survival (OS) and disease progression-free survival (PFS) of cervical cancer patients (χ2=4.324, 8.068,P<0.05). The expression of MMP-9 was related with PFS (χ2=5.134,P<0.05). Patients with PBK and MMP-9 expression suffered poor OS and PFS (χ2=5.382, 9.364,P<0.05). Conclusions PBK and MMP-9 could be a biomarker to predict the prognosis of cervical cancer.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭